PLRX Pliant Therapeutics Inc.
Upcoming Catalysts
| Drug | Stage | Catalyst Date |
|---|---|---|
|
PLN-1474
Liver fibrosis associated with NASH
|
Phase 1
Phase 1
|
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
|
|
PLN-74809
Idiopathic pulmonary fibrosis
|
Phase 2a
Phase 2a
|
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
|
Drug Pipeline
| Drug | Stage | Notes |
|---|---|---|
|
PLN-74809
Primary sclerosing cholangitis
|
Phase 2a
Phase 2a
|
Phase 2a trial enrolling.
|
Latest News
-
View Full Article Hide Full Article
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that management will be participating in the following virtual investor events in March:
- Cowen 41st Annual Health Care Conference – March 1-4, 2021. Bernard Coulie, M.D., Ph.D., Pliant's President and Chief Executive Officer, will participate in the Respiratory/Infections Panel discussion on March 1, 2021 at 10:30 a.m. ET/ 7:30 a.m. PT and, along with members of Pliant's senior management team, will conduct one-on-one meetings with members of the investment community.
The Cowen Respiratory/Infections Panel will stream live and have a replay available on Cowen's Conference Site.
- Citi's 2021 Winter West Coast Biotech Virtual Bus Tour - March 16-17, 2021. Pliant senior management will be meeting with investors on March 17, 2021.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook, and YouTube.Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
[email protected]
- Cowen 41st Annual Health Care Conference – March 1-4, 2021. Bernard Coulie, M.D., Ph.D., Pliant's President and Chief Executive Officer, will participate in the Respiratory/Infections Panel discussion on March 1, 2021 at 10:30 a.m. ET/ 7:30 a.m. PT and, along with members of Pliant's senior management team, will conduct one-on-one meetings with members of the investment community.
-
View Full Article Hide Full Article
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. David Pyott, former Chairman and Chief Executive Officer of Allergan, to Pliant's Board of Directors.
"David is an accomplished international pharmaceutical executive whose extensive experience in building companies will be invaluable at this stage of Pliant's development," said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. "It is my great pleasure to welcome David to the Board and look forward to his insights as we advance and expand our clinical stage portfolio."
Dr. Pyott joins the Pliant Board of Directors with more than 30 years of executive leadership and management experience within the global pharmaceutical industry. Dr. Pyott most recently served as Chairman and Chief Executive Offer of Allergan, where, over his 17-year tenure in this role, he transformed the company from a small eye care business with $1 billion in annual sales into a global specialty pharmaceutical and medical device company with 2014 annual sales of over $7 billion. Prior to Allergan, Dr. Pyott held the role of Head of the Novartis Nutrition Division and served as a member of the Executive Committee of Switzerland-based Novartis AG.
"I am excited to be joining the Pliant board and supporting an accomplished group of board members and a strong leadership team to help guide the company's mission of delivering innovative and potential transformative treatments to patients," said Dr. Pyott. "I believe Pliant's novel approach has the potential to address the need for new treatments for fibrotic diseases."
In addition to Pliant, Dr. Pyott currently serves as a member of the Board of Directors of Alnylam Pharmaceuticals and BioMarin Pharmaceutical, as Chairman of Bioniz Therapeutics, Inc., a private biotechnology company, and is a member of the Supervisory Board of Royal Philips in the Netherlands, a public diversified health technology company. Dr. Pyott serves as Deputy Chairman of the Governing Board of the London Business School, President of the Ophthalmology Foundation, President of the Advisory Board of the American Academy of Ophthalmology and is also a Trustee of the California Institute of Technology.
Dr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, an Honorary Degree in Medicine and a Master of Arts degree from the University of Edinburgh, and a Master of Business Administration degree from the London Business School.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, and Facebook.Investor Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
[email protected]Media Contact:
Cambria Fuqua
Canale Communications
[email protected]A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/95826a4d-80dc-482a-aab1-c8684bfa48e5
-
View Full Article Hide Full Article
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Gregory P. Cosgrove, M.D., FCCP, as Pliant's Vice President of Clinical Development. Dr. Cosgrove brings over 20 years of pulmonary and critical care expertise in academic clinical research to Pliant and in this role, will lead the strategic execution of the company's Idiopathic Pulmonary Fibrosis (IPF) clinical development program with its lead compound PLN-74809. PLN-74809 is a dual selective inhibitor of αvβ6/αvβ1, in clinical development for the treatment of IPF, primary sclerosing cholangitis (PSC), and COVID-19-associated acute respiratory distress syndrome (ARDS).
"Greg's extensive scientific and clinical expertise in the area of pulmonary fibrosis, as well as his strong relationships within the research, clinical investigator, and patient communities, will be instrumental as we further implement the development strategy of our novel IPF program," said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant Therapeutics. "I look forward to working with Greg and utilizing his broad experiences to enhance our clinical development efforts and support the progress of PLN-74809."
Dr. Cosgrove most recently served as the Chief Medical Officer of the Pulmonary Fibrosis Foundation, a leading nonprofit organization dedicated to assisting patients and identifying effective treatments and a cure for those living with pulmonary fibrosis. Concurrently, Dr. Cosgrove also held the roles of Associate Professor within the pulmonology divisions of the University of Colorado-Denver and National Jewish Health Departments of Medicine. Dr. Cosgrove has served as principal or sub investigator in more than 15 clinical trials evaluating IPF drug candidates, authored or contributed to over 70 publications and books in pulmonology research, and served as a reviewer for numerous scientific peer-reviewed journals.
Dr. Cosgrove commented, "As a physician, researcher and advocate, I believe patients are a cornerstone to changing the landscape in pulmonary fibrosis. I am excited to join a team that shares my commitment to the patient and to advancing treatments for IPF and other fibrotic diseases."
Dr. Cosgrove received his B.S., magna cum laude, from James Madison University with highest honors in chemistry and his M.D. from the Hahnemann University School of Medicine in Philadelphia. Dr. Cosgrove completed his residency in internal medicine and post-doctoral fellowships at the University of Colorado Health Sciences Center Denver and the National Jewish Medical and Research Center Denver, respectively.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, and Facebook.Investor Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
[email protected]Media Contact:
Cambria Fuqua
Canale Communications
cambria.fuqua@canalecomm.comA photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d92466b0-df39-4775-b95e-17fc5f8190ad.
-
View Full Article Hide Full Article
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced its participation in the Piper Sandler 32nd Annual Healthcare Conference to be held virtually December 1 – 3, 2020.
Bernard Coulie, M.D., Ph.D., president and chief executive officer of Pliant Therapeutics, will participate in a fireside chat with Tyler M. Van Buren, senior biotechnology analyst at Piper Sandler. The fireside chat will be pre-recorded and available beginning on Monday, November 23, 2020 at 10:00 am ET by visiting the "News & Events" section of the "Investors & Media" page of the Pliant Therapeutics' website at www.pliantrx.com.
The webcast replay of the fireside chat will be archived for 90 days following the conclusion of the event.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, and Facebook.Investor Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
[email protected]Media Contact:
Cambria Fuqua
Canale Communications
[email protected]
View original content to download multimedia:http://www.prnewswire.com/news-releases/pliant-therapeutics-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference-301176485.htmlSOURCE Pliant Therapeutics, Inc.
-
View Full Article Hide Full Article
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) (the Company), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported third quarter 2020 financial results.
"Reflecting back on the first three quarters of 2020, I'm proud of the progress we've made despite the challenges related to the COVID-19 pandemic," said Bernard Coulie, M.D., Ph.D., Chief Executive Officer and President of Pliant Therapeutics. "We closed a successful IPO, took important steps in advancing our clinical programs across four indications, and further strengthened our leadership team. Looking ahead, with a strong cash position to advance our robust pipeline, we remain deeply committed to bringing novel treatments to people with fibrotic diseases."
Recent Highlights
- Enrollment of Phase 2a 12-week trials of PLN-74809 in idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) progressing. After resuming enrollment earlier in the year, Pliant has remained in close coordination with its global trial sites in order to facilitate enrollment in both Phase 2a trials. The Company also continues to open additional trial sites as COVID-19 related restrictions are eased. The hybrid approach to clinical trial participation utilizing home-health solutions to maximize patient safety is expected to aid in trial recruitment.
- Phase 2a PET imaging trial of PLN-74809 in IPF is enrolling. The Phase 2a PET trial will evaluate safety, tolerability, and target engagement of PLN-74809 in IPF patients. We expect to report preliminary data by the first half of 2021.
- Completed dosing of an extended Phase 1 dose escalation trial of PLN-74809 in healthy volunteers. PLN-74809 has completed dosing multiple ascending dose cohorts of 120mg and 160mg once daily in an extended dose escalation trial. The pharmacokinetic profile remains in line with previous cohorts, and PLN-74809 remains generally well tolerated with no drug related severe adverse events or serious adverse events reported in either cohort.
- Phase 2a trial of PLN-74809 treatment of COVID-19 related acute respiratory distress syndrome (ARDS) has been initiated. The Company initiated a Phase 2a trial evaluating safety, tolerability and pharmacokinetics (PK) of PLN-74809, as well as exploratory clinical outcome measures in patients hospitalized with severe and critical COVID-19.
- Phase 1 trial of PLN-1474 in healthy volunteers is nearing completion. The Phase 1 trial is designed to evaluate safety and tolerability, as well as PK of PLN-1474 in approximately 100 healthy volunteers across a dose range compared to placebo. After resuming enrollment following delays related to COVID-19, the trial remains on track to deliver topline data by the first quarter of 2021. PLN-1474 is partnered with Novartis.
COVID-19 Preparedness
Pliant continues to develop policies and procedures to enable the Company to operate safely and productively during the COVID-19 pandemic. The Company has experienced delays in clinical trial operations which have impacted, and may further impact the expected timing of data readouts. Pliant is working closely with clinical sites to continue site initiation and operation activities in compliance with study protocols while observing government and institutional guidelines. The Company intends to provide more specific guidance regarding clinical trial progress and the timing of data readouts as the impacts of the pandemic become better understood.
Third-Quarter 2020 Financial Results
- Related party revenue was $4.8 million, as compared to none for the prior-year quarter.
- Research and development expenses were $16.9 million, as compared to $10.8 million for the prior-year quarter. The increase was due primarily to higher costs related to the advancement of several programs and ongoing Phase 1/2 clinical trials.
- General and administrative expenses were $4.6 million, as compared to $2.6 million for the same period in 2019. The increase was due to higher personnel-related and professional services expenses.
- Net loss of $16.5 million as compared to a net loss of $13.3 million for the prior-year quarter.
- As of September 30, 2020, Pliant had cash, cash equivalents and short-term investments of $294.0 million, compared to $312.5 million as of June 30, 2020. Pliant believes it has sufficient funds to meet its operating and capital requirements into 2023.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, and Facebook.Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding our product candidates, including their development and therapeutic potential, the advancement of our clinical and preclinical pipeline, including the timing, enrollment and results of our clinical trials, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical trials, clinical supply and plans, our collaboration with Novartis for PLN-1474 and the intended benefits of such collaborations, and our financial position and cash runway. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and plans, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our prospectus dated June 3, 2020 as filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act 1933, as amended, and the Quarterly Report for the second quarter of 2020 filed with the SEC on Form 10-Q on August 11, 2020 which are available on the SEC's website at www.sec.gov. Additional information will be made available in Pliant Therapeutics quarterly report on Form 10-Q for the quarter ended September 30, 2020 forward looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.Investor Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
[email protected]Media Contact:
Cambria Fuqua
Canale Communications
[email protected]Pliant Therapeutics, Inc.
Condensed Statements of Operations and Comprehensive Loss
(Unaudited)
(In thousands, except number of shares and per share amounts)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020
2019
2020
2019
Revenue — related party
$
4,814
$
—
$
37,352
$
—
Operating expenses:
Research and development
(16,884)
(10,779)
(48,339)
(35,626)
General and administrative
(4,591)
(2,583)
(11,642)
(7,827)
Total operating expenses
(21,475)
(13,362)
(59,981)
(43,453)
Loss from operations
(16,661)
(13,362)
(22,629)
(43,453)
Interest income
72
148
392
701
Other income (expense), net
55
(41)
(269)
(48)
Net loss
$
(16,534)
$
(13,255)
$
(22,506)
$
(42,800)
Accretion to redemption value and cumulative dividends on
redeemable convertible preferred stock
—
(1,375)
—
(4,078)
Net loss attributable to common stockholders
$
(16,534)
$
(14,630)
$
(22,506)
$
(46,878)
Net loss per share, attributable to common stockholders:
Basic
$
(0.47)
$
(8.53)
$
(1.36)
$
(30.03)
Diluted
$
(0.47)
$
(8.53)
$
(1.36)
$
(30.03)
Shares used in computing net loss per share attributable
to common stockholders:
Basic
35,445,504
1,714,285
16,592,746
1,561,242
Diluted
35,445,504
1,714,285
16,592,746
1,561,242
Comprehensive loss:
Net loss
$
(16,534)
$
(13,255)
$
(22,506)
$
(42,800)
Net unrealized gain (loss) on short-term investments
$
12
$
(10)
$
(17)
$
1
Total other comprehensive income (loss)
12
(10)
(17)
1
Comprehensive loss
$
(16,522)
$
(13,265)
$
(22,523)
$
(42,799)
Pliant Therapeutics, Inc.
Condensed Balance Sheets
(Unaudited)
(In thousands, except number of shares and per share amounts)
September 30,
2020
December 31,
2019
Assets
Current assets
Cash and cash equivalents
$
55,224
$
85,807
Short-term investments
238,776
16,966
Accounts receivable
7,131
7,052
Tax credit receivable
83
333
Prepaid expenses and other current assets
6,515
1,742
Total current assets
307,729
111,900
Property and equipment, net
4,144
4,079
Other non-current assets
451
3,085
Total assets
$
312,324
$
119,064
Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity
(Deficit)Current liabilities
Accounts payable
$
3,140
$
1,250
Accrued liabilities (Note 5)
7,886
6,922
Total current liabilities
11,026
8,172
Other long-term liabilities (Note 5)
952
912
Total liabilities
11,978
9,084
Commitments and Contingencies (Note 13)
Preferred stock, $0.0001 par value; 10,000,000 shares and 0 shares
authorized at September 30, 2020 and December 31, 2019, respectively;
0 shares issued and outstanding at September 30, 2020
and December 31, 2019;—
—
Series A redeemable convertible preferred stock, $0.0001 par value;
0 and 56,000,000 shares authorized at September 30, 2020
and December 31, 2019, respectively; 0 and 56,000,000 shares
issued and outstanding, at September 30, 2020 and December 31, 2019,
respectively; aggregate liquidation preference of $0 and
$62,468 at September 30, 2020 and December 31, 2019, respectively;—
62,468
Series B redeemable convertible preferred stock, $0.0001 par value;
0 shares and 49,501,221 shares authorized at September 30, 2020 and
December 31, 2019, respectively; 0 shares and 49,501,221 shares
issued and outstanding at September 30, 2020 and December 31, 2019,
respectively; aggregate liquidation preference of $0 and $75,860
at September 30, 2020 and December 31, 2019, respectively;—
75,860
Series C redeemable convertible preferred stock, $0.0001 par value;
0 shares and 44,000,000 shares authorized at September 30, 2020 and
December 31, 2019, respectively; 0 shares and 26,360,745 shares
issued and outstanding at September 30, 2020 and December 31, 2019,
respectively; aggregate liquidation preference of $0 and $47,947
at September 30, 2020 and December 31, 2019, respectively;—
47,947
Stockholders' equity (deficit)
Common stock, $0.0001 par value; 300,000,000 and 181,000,000 shares authorized
at September 30, 2020 and December 31, 2019; and 35,465,715 and 1,846,024 shares
issued and outstanding at September 30, 2020 and December 31, 2019, respectively;3
1
Additional paid-in capital
399,162
—
Accumulated deficit
(98,801)
(76,295)
Accumulated other comprehensive loss
(18)
(1)
Total stockholders' equity (deficit)
300,346
(76,295)
Total liabilities, redeemable convertible preferred stock and stockholders' equity
(deficit)$
312,324
$
119,064
View original content to download multimedia:http://www.prnewswire.com/news-releases/pliant-therapeutics-provides-corporate-update-and-reports-third-quarter-2020-financial-results-301170058.htmlSOURCE Pliant Therapeutics, Inc.